Z M Younossi

Summary

Affiliation: Inova Fairfax Hospital
Country: USA

Publications

  1. ncbi request reprint Nonalcoholic fatty liver disease in patients with type 2 diabetes
    Zobair M Younossi
    The Cleveland Clinic Foundation, Cleveland, USA
    Clin Gastroenterol Hepatol 2:262-5. 2004
  2. ncbi request reprint Nonalcoholic fatty liver disease: an agenda for clinical research
    Zobair M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Hepatology 35:746-52. 2002
  3. ncbi request reprint A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease
    Zobair M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Hepatology 42:665-74. 2005
  4. doi request reprint A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment
    Z M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Annandale, VA 22003 6800, USA
    J Viral Hepat 15:370-8. 2008
  5. ncbi request reprint Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C
    Zobair M Younossi
    Inova Fairfax Hospital, Center for Liver Diseases, Department of Medicine, Falls Church, Virginia 22042, USA
    Dig Dis Sci 50:970-5. 2005
  6. ncbi request reprint The effects of HCV infection and management on health-related quality of life
    Zobair Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Inova Outcomes Research Program, Inova Health System, Falls Church, VA, Annandale, VA 22003, USA
    Hepatology 45:806-16. 2007
  7. ncbi request reprint Obesity and non-alcoholic fatty liver disease in chronic hepatitis C
    Zobair M Younossi
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, Virginia 22042, USA
    J Clin Gastroenterol 38:705-9. 2004
  8. ncbi request reprint Impact of liver transplantation on health-related quality of life
    Z M Younossi
    Liver Transplant Center, The Cleveland Clinic Foundation, Cleveland, OH, USA
    Liver Transpl 6:779-83. 2000
  9. ncbi request reprint Interferon alpha 2B and ribavirin in severe recurrent cholestatic hepatitis C
    J P Ong
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Transplantation 71:1486-7. 2001
  10. ncbi request reprint Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C
    Z M Younossi
    Department of Gastroenterology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Hepatology 30:1318-24. 1999

Detail Information

Publications113 found, 100 shown here

  1. ncbi request reprint Nonalcoholic fatty liver disease in patients with type 2 diabetes
    Zobair M Younossi
    The Cleveland Clinic Foundation, Cleveland, USA
    Clin Gastroenterol Hepatol 2:262-5. 2004
    ..The aim of this study was to assess the outcome of patients with NAFLD and DM...
  2. ncbi request reprint Nonalcoholic fatty liver disease: an agenda for clinical research
    Zobair M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Hepatology 35:746-52. 2002
  3. ncbi request reprint A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease
    Zobair M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Hepatology 42:665-74. 2005
    ..These findings may help clarify the pathogenesis of NAFLD and identify potential targets for therapeutic intervention...
  4. doi request reprint A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment
    Z M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Annandale, VA 22003 6800, USA
    J Viral Hepat 15:370-8. 2008
    ..Future randomized clinical trials are needed to establish the impact of growth factors in improving sustained virological response...
  5. ncbi request reprint Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C
    Zobair M Younossi
    Inova Fairfax Hospital, Center for Liver Diseases, Department of Medicine, Falls Church, Virginia 22042, USA
    Dig Dis Sci 50:970-5. 2005
    ..29 vs. 20%; P = 0.04). Age, gender, and BMI did not affect SVR. The addition of amantadine to pegylated interferon alpha-2b and ribavirin does not seem to increase the efficicacy of this regimen...
  6. ncbi request reprint The effects of HCV infection and management on health-related quality of life
    Zobair Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Inova Outcomes Research Program, Inova Health System, Falls Church, VA, Annandale, VA 22003, USA
    Hepatology 45:806-16. 2007
    ..Several new drugs with the potential to increase SVR rates without compromising HRQL are in development...
  7. ncbi request reprint Obesity and non-alcoholic fatty liver disease in chronic hepatitis C
    Zobair M Younossi
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, Virginia 22042, USA
    J Clin Gastroenterol 38:705-9. 2004
    ..Superimposed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) may affect HCV-related fibrosis. We performed a study to determine the relationship between NAFLD and chronic hepatitis C...
  8. ncbi request reprint Impact of liver transplantation on health-related quality of life
    Z M Younossi
    Liver Transplant Center, The Cleveland Clinic Foundation, Cleveland, OH, USA
    Liver Transpl 6:779-83. 2000
    ..Similar improvements were evident in physical and disease-specific aspects of health-related quality of life, but some residual dysfunction persisted...
  9. ncbi request reprint Interferon alpha 2B and ribavirin in severe recurrent cholestatic hepatitis C
    J P Ong
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Transplantation 71:1486-7. 2001
    ..Combination of interferon and ribavirin was given with prompt virological suppression. Despite this rapid viral suppression, all four patients developed progressive graft failure with three deaths...
  10. ncbi request reprint Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C
    Z M Younossi
    Department of Gastroenterology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Hepatology 30:1318-24. 1999
    ..We conclude that combination of IFN and ribavirin with duration of therapy based on the viral genotype, is a cost-effective approach in treating patients with chronic hepatitis C...
  11. doi request reprint Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C
    A Birerdinc
    Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA 22042, USA
    J Viral Hepat 17:730-6. 2010
    ..In addition, focal adhesion and TGF-β pathways are associated with some predictors of response...
  12. ncbi request reprint Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease
    J Ong
    Department of Gastroenterology, The Cleveland Clinic Foundation, Cleveland, OH, USA
    Liver Transpl 7:797-801. 2001
    ..Post-OLT NAFL and NASH can be seen in a number of patients with cryptogenic cirrhosis. This supports the notion that some cases of cryptogenic cirrhosis represent burned-out NAFL...
  13. doi request reprint Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C)
    A Birerdinc
    Center for Liver Disease and Department of Medicine, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    J Viral Hepat 19:414-22. 2012
    ..In particular, we identified the hypoxia response pathway and the apoptosis/survival-related gene network, as differentially expressed in chronic hepatitis C patients with anaemia...
  14. ncbi request reprint A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy
    Z M Younossi
    Department of Gastroenterology, Biostatistics and Anatomic Pathology, The Cleveland Clinic Foundation, OH, USA
    J Hepatol 34:128-33. 2001
    ..Although IFN + RIBA in this group was associated with a reasonable end of treatment response, relapses were common and sustained responses were low...
  15. doi request reprint Vietnamese community screening for hepatitis B virus and hepatitis C virus
    J B Kallman
    Center for Liver Diseases Outcomes Research Program, Inova Fairfax Hospital, Betty and Guy Beatty Center for Integrated Research, Falls Church, VA, USA
    J Viral Hepat 18:70-6. 2011
    ..Nevertheless, the rate for HBV vaccination was low. The low prevalence of abnormal liver enzymes in HBV-positive subjects emphasizes the need for screening to be triggered by risk factors and not by abnormal liver enzymes...
  16. ncbi request reprint Assessment of utilities and health-related quality of life in patients with chronic liver disease
    Z M Younossi
    Department of Gastroenterology, The Cleveland Clinic Foundation, Ohio, USA
    Am J Gastroenterol 96:579-83. 2001
    ..quot; CONCLUSIONS: We conclude that utilities should be based on patient reports and that the data from this study can inform economic analyses in studies of patients with chronic liver disease...
  17. doi request reprint Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C
    Z M Younossi
    Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Aliment Pharmacol Ther 37:703-9. 2013
    ..The impact of moderate alcohol consumption on long-term outcomes of chronic hepatitis C (CH-C) infected patients remains controversial...
  18. doi request reprint Predictors of health-related quality of life in patients with chronic liver disease
    A Afendy
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA
    Aliment Pharmacol Ther 30:469-76. 2009
    ..Patient-reported outcomes like health-related quality of life (HRQL) have become increasingly important for full assessment of patients with chronic liver diseases (CLD)...
  19. ncbi request reprint Adipokines and cytokines in non-alcoholic fatty liver disease
    M H Jarrar
    Translational Research Institute, Inova Health System, Fairfax, VA, USA
    Aliment Pharmacol Ther 27:412-21. 2008
    ..Several adipocytokines have been implicated in the pathogenesis non-alcoholic fatty liver disease (NAFLD)...
  20. ncbi request reprint Health-related quality of life in chronic liver disease: the impact of type and severity of disease
    Z M Younossi
    The Cleveland Clinic Foundation, Ohio, USA
    Am J Gastroenterol 96:2199-205. 2001
    ..CONCLUSIONS: We conclude that chronic liver disease substantially reduces HRQL, and this impact does not differ markedly by type of disease. Older age and measures of disease severity were associated with poorer HRQL...
  21. doi request reprint Mortality associated with alcohol-related liver disease
    G Trimble
    Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Aliment Pharmacol Ther 38:596-602. 2013
    ..Excessive alcohol use has been reported to be responsible for 80 000 annual deaths in the United States. However, the exact cause of death related to the excessive use of alcohol has not been fully explored...
  22. doi request reprint Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity
    M Stepanova
    Center for Liver Diseases and Department of Medicine, Inova Fairfax Hospital Betty, Inova Health System, Falls Church, VA, USA
    J Viral Hepat 19:341-5. 2012
    ....
  23. ncbi request reprint Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients
    Janus P Ong
    Center for Liver Diseases, Inova Fairfax Hospital, Washington, DC, USA
    Obes Surg 15:310-5. 2005
    ..We report the prevalence of NAFLD and NASH as well as predictors of NASH and advanced fibrosis in morbidly obese patients...
  24. ncbi request reprint Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin
    Zobair M Younossi
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Hepatology 49:763-74. 2009
    ..Conclusion: Early gene expression during anti-HCV therapy may elucidate important molecular pathways that may be influencing the probability of achieving virologic response...
  25. ncbi request reprint Triple combination of interferon alpha-2b, ribavirin, and amantadine for treatment of chronic hepatitis C
    Zobair M Younossi
    The Cleveland Clinic Foundation, Ohio, USA
    J Clin Gastroenterol 36:427-30. 2003
    ..In this interferon-resistant group, a treatment regimen of interferon alpha-2b, ribavirin, and amantadine was associated with only a 10% sustained viral eradication rate...
  26. doi request reprint Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease
    A Baranova
    Betty and Guy Beatty Center for Integrated Research, Inova Health System, 3300 Gallows Road, Falls Church, VA 22042, USA
    Aliment Pharmacol Ther 33:801-14. 2011
    ..Polycystic ovary syndrome (PCOS) is a common disorder for women of child-bearing age and is associated with metabolic syndrome (MS)...
  27. ncbi request reprint Health-related quality of life in patients with non-alcoholic fatty liver disease
    A A Dan
    Center for Liver Diseases, Inova Fairfax Hospital, and INOVA Outcomes Research Program, Inova Health System, Falls Church, VA, USA
    Aliment Pharmacol Ther 26:815-20. 2007
    ..The relative impact of non-alcoholic fatty liver disease (NAFLD) on health-related quality of life (HRQL) compared to other chronic liver diseases has not been fully explored...
  28. ncbi request reprint Chronic hepatitis C and superimposed nonalcoholic fatty liver disease
    J P Ong
    Department of Gastroenterology and Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Liver 21:266-71. 2001
    ..5%), males (62%) with 16% having type 2 diabetes and a BMI 33.8+/-7.12. CONCLUSION: In patients with chronic hepatitis C, type 2 DM and superimposed steatohepatitis are independently associated with advanced fibrosis...
  29. doi request reprint Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease
    M Estep
    Betty and Guy Beatty Center for Integrated Research, Falls Church, VA 22042, USA
    Aliment Pharmacol Ther 32:487-97. 2010
    ..MicroRNAs (miRNAs) are likely to regulate some of these molecular pathways involved in pathogenesis of NAFLD...
  30. ncbi request reprint Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis
    Zobair M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA
    Liver Int 25:760-71. 2005
    ..NAFLD includes a spectrum of clinicopathologic syndromes that includes non-alcoholic steatohepatitis (NASH) that has potential for progression. The pathogenesis of NASH is poorly characterized...
  31. doi request reprint Expression of cytokine signaling genes in morbidly obese patients with non-alcoholic steatohepatitis and hepatic fibrosis
    J Michael Estep
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA, 22042, USA
    Obes Surg 19:617-24. 2009
    ..The aim of this study was to assess the association of hepatic fibrosis and NASH by evaluating the intrinsic differences in the inflammatory cytokine signaling in the visceral adipose tissue obtained from morbidly obese patients...
  32. ncbi request reprint Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life
    Amy A Dan
    Center for Liver Diseases, Dept of Psychiatry, Inova Fairfax Hospital, Annandale, VA 22003 6800, USA
    Psychosomatics 48:223-9. 2007
    ..Greater anger was associated with more depression and poorer HRQL. Findings point to the importance for physicians to screen for a wide range of neuropsychiatric side effects of interferon, including anger...
  33. ncbi request reprint Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia
    Janus P Ong
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Cleve Clin J Med 71:S17-21. 2004
    ..The impact of growth factors on sustained virologic response and their cost-effectiveness in patients with chronic hepatitis C need further assessment...
  34. doi request reprint Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study
    L Gerber
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA
    Aliment Pharmacol Ther 36:772-81. 2012
    ..High intensity exercise improves metabolic status and may potentially mobilise hepatic fat...
  35. doi request reprint Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study
    A Sanyal
    Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University School of Medicine, Richmond, VA, USA
    Aliment Pharmacol Ther 34:853-61. 2011
    ..Recurrent bouts of overt HE negatively impact daily functioning and quality of life...
  36. ncbi request reprint Predictors of mortality and resource utilization in cirrhotic patients admitted to the medical ICU
    A Aggarwal
    Department of Gastroenterology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Chest 119:1489-97. 2001
    ..001). CONCLUSION: Simple prognostic models for mortality and resource utilization have been developed for cirrhotic patients admitted to the MICU...
  37. ncbi request reprint A pharmacoeconomic appraisal of therapies for hepatitis B and C
    Z M Younossi
    I.H. Page Center for Health Outcomes Research and Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042-3300, USA
    Expert Opin Pharmacother 2:205-11. 2001
    ..In this article, we will discuss the clinical aspects of hepatitis B and C, recent advances in treatment and studies of the cost-effectiveness of these treatments...
  38. doi request reprint Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Z M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA
    Aliment Pharmacol Ther 28:2-12. 2008
    ..Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome...
  39. doi request reprint Screening for hepatitis B, C and non-alcoholic fatty liver disease: a survey of community-based physicians
    J B Kallman
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Rd, Falls Church, VA 22042, USA
    Aliment Pharmacol Ther 29:1019-24. 2009
    ....
  40. doi request reprint Nutritional assessments of patients with non-alcoholic fatty liver disease
    Chin Hee Kim
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Obes Surg 20:154-60. 2010
    ..Obesity is not only associated with nonalcoholic fatty liver disease (NAFLD) but it also adversely affects the progression of other liver diseases. There are limited data regarding the dietary habits of patients with chronic liver disease...
  41. ncbi request reprint Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection
    Jillian Kallman
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, 3289 Woodburn Road, Suite 375, Annandale, Virginia 22003, USA
    Dig Dis Sci 52:2531-9. 2007
    ..Chronic HCV infection has a profound negative impact on patients' HRQL. Disabling fatigue is the most important factor that contributes to loss of well-being in this relatively young group of patients...
  42. ncbi request reprint The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin
    Rochelle S Collantes
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA 22042, USA
    J Clin Gastroenterol 39:S9-13. 2005
    ....
  43. doi request reprint Associations of chronic hepatitis C with metabolic and cardiac outcomes
    Z M Younossi
    Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA
    Aliment Pharmacol Ther 37:647-52. 2013
    ..Chronic hepatitis C virus (CH-C) infection is associated with metabolic conditions such as insulin resistance and type 2 diabetes (DM) and may increase the risk of cardiovascular diseases...
  44. doi request reprint Caffeine is protective in patients with non-alcoholic fatty liver disease
    A Birerdinc
    Center for Liver Disease and Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA
    Aliment Pharmacol Ther 35:76-82. 2012
    ..Although recent studies have found that coffee drinking is protective against end stage chronic liver disease, there are scarce caffeine intake data in NAFLD specifically...
  45. ncbi request reprint Survival and resource utilization in liver transplant recipients: the impact of admission to the intensive care unit
    A Aggarwal
    Department of Gastroenterology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Transplant Proc 35:2998-3002. 2003
    ....
  46. ncbi request reprint Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults
    M E Singer
    Department of Epidemiology and Biostatistics, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
    Am J Med 111:614-21. 2001
    ..5%. Screening with PCR only was never cost effective. CONCLUSIONS: This analysis does not support the widespread screening for hepatitis C among asymptomatic, average-risk adults...
  47. ncbi request reprint The metabolic syndrome and nonalcoholic fatty liver disease
    R S Collantes
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Panminerva Med 48:41-8. 2006
    ..Future therapies may combine drugs that target specific pathways involved in NAFLD pathogenesis...
  48. doi request reprint Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
    G Vernon
    Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Aliment Pharmacol Ther 34:274-85. 2011
    ..This study assesses the epidemiology of NAFLD in adults based on clinical literature published over the past 30 years...
  49. doi request reprint Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease
    Janus P Ong
    Center for Liver Diseases, Inova Fairfax Hospital, Annandale, VA 22003, USA
    J Hepatol 49:608-12. 2008
    ..The natural history of non-alcoholic fatty liver disease (NAFLD) remains to be defined. We conducted a study to determine the overall and liver-related mortality of NAFLD in the general US population...
  50. doi request reprint Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis
    Poonam Mishra
    Center for Liver Diseases, Inova Fairfax Hospital, Annandale, VA 22033, USA
    Liver Int 28:1080-6. 2008
    ..This study evaluates the potential association between the NAFLD subtypes and a number of polysomnographical (PSG) parameters...
  51. ncbi request reprint Depression, anemia and health-related quality of life in chronic hepatitis C
    Amy A Dan
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, 3289 Woodburn Road, Suite 375, Annandale, VA 22003 6800, USA
    J Hepatol 44:491-8. 2006
    ..Hepatitis C (HCV) infected patients have significant health-related quality of life (HRQL) impairment which worsens during anti-viral therapy. Our aim was to examine the association of HRQL with treatment-induced depression and anemia...
  52. ncbi request reprint High rates of uninsured among HCV-positive individuals
    Janus P Ong
    Center for Liver Diseases, Inova Fairfax Hospital, Annandale, VA 22003, USA
    J Clin Gastroenterol 39:826-30. 2005
    ..There are no published data on the health insurance status of Hepatitis C virus (HCV)-positive individuals. To address this issue, we analyzed data from the Third National Health and Nutrition Examination Survey (NHANES III)...
  53. doi request reprint The impact of chronic hepatitis C on resource utilisation and in-patient mortality for Medicare beneficiaries between 2005 and 2010
    Z M Younossi
    Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA
    Aliment Pharmacol Ther 38:1065-75. 2013
    ..As baby boomers age, chronic hepatitis C (CHC) will become increasingly important in Medicare eligible group...
  54. ncbi request reprint Health-related quality of life (HRQL) in chronic liver disease
    L M Martin
    Center for Liver Diseases, Inova Fairfax Hospital, Annandale, VA 22003, USA
    Dig Liver Dis 37:819-20. 2005
  55. ncbi request reprint Mushroom poisoning--from diarrhea to liver transplantation
    C N Broussard
    Department of Gastroenterology, The Cleveland Clinic Foundation, Ohio, USA
    Am J Gastroenterol 96:3195-8. 2001
    ..Use of i.v. penicillin G is supported by most reports. Silibinin, although preferred over penicillin, is not easily available in the United States. In those with acute liver failure, liver transplantation can be life saving...
  56. ncbi request reprint Clinical features and natural history of nonalcoholic steatosis syndromes
    Y Falck-Ytter
    Schwartz Center for Metabolism and Nutrition, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA
    Semin Liver Dis 21:17-26. 2001
    ..However, a number of important unresolved issues must be clarified before the true natural history of this disease can be fully understood...
  57. ncbi request reprint Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease
    Ancha Baranova
    Center for Liver Diseases, Inova Fairfax Hospital, Fairfax, VA 22042, USA
    Obes Surg 17:1111-8. 2007
    ..Differences in transcriptional regulation in omental adipose tissue and liver tissue may provide important insights into the pathogenesis of NAFLD and its progression...
  58. doi request reprint Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C
    Zobair M Younossi
    Center for Liver Diseases at Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Liver Int 29:1403-12. 2009
    ..Hepatic steatosis occurs in 40-70% of patients chronically infected with hepatitis C virus [chronic hepatitis C (CH-C)]. Hepatic steatosis in CH-C is associated with progressive liver disease and a low response rate to antiviral therapy...
  59. ncbi request reprint Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery
    Savita Srivastava
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA
    Hepatology 42:490-2. 2005
    ..This study examines the impact of biliopancreatic diversion, a malabsorptive variant of gastric bypass, on liver histology...
  60. ncbi request reprint Predictors of long-term mortality in patients with cirrhosis of the liver admitted to a medical ICU
    Thomas R Gildea
    Department of Pulmonary and Critical Care Medicine, The Cleveland Clinic Foundation, 9500 Euclid Ave, G62, Cleveland, OH 44195, USA
    Chest 126:1598-603. 2004
    ..The long-term survival of patients with cirrhosis of the liver admitted to the ICU has not been described...
  61. doi request reprint Effects of weight loss on nonalcoholic fatty liver disease
    Nila Rafiq
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Virginia 22042, USA
    Semin Liver Dis 28:427-33. 2008
    ..On the other hand, the literature lacks well-designed, randomized control trials that assess the efficacy of anti-obesity regimens on histologic and long-term outcomes of NAFLD...
  62. pmc Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study
    Winston Dunn
    Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, California, USA
    Am J Gastroenterol 103:2263-71. 2008
    ..The current study compared the survival of subjects with and without suspected NAFLD in a population-based cohort, and placed the finding in the context of previously published case series...
  63. doi request reprint Hepatic stellate cell and myofibroblast-like cell gene expression in the explanted cirrhotic livers of patients undergoing liver transplantation
    J Michael Estep
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Dig Dis Sci 55:496-504. 2010
    ..Hepatic stellate cells (HSC) are involved in hepatic fibrogenesis. Cell signaling associated with an insult to the liver affects an HSC transdifferentiation to fibrogenic myofibroblast-like cells...
  64. ncbi request reprint Current treatment strategies for non-alcoholic fatty liver disease (NAFLD)
    Poonam Mishra
    Center for Liver Diseases at Inova Fairfax Hospital, Annandale, Virginia 22042, USA
    Curr Drug Discov Technol 4:133-40. 2007
    ..NAFLD treatment currently focuses on reducing metabolic risk factors, with the mainstay of therapy focusing on life-style modifications such as gradual weight loss through diet and regular exercise...
  65. ncbi request reprint The role of genomics and proteomics: technologies in studying non-alcoholic fatty liver disease
    Ancha Baranova
    Center for Liver Diseases, Inova Fairfax Hospital, Department of Medicine, Falls Church, VA 22042, USA
    Clin Liver Dis 11:209-20, xi. 2007
    ..For this reason, high-throughput approaches may be well suited for studies designed to untangle the molecular basis of the chronic liver diseases such as NAFLD...
  66. doi request reprint Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis
    Zobair M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Virginia 22042, USA
    J Proteome Res 9:3218-24. 2010
    ..Phosphoproteomics technology could potentially be used to provide pathogenic information about NASH and NASH-related fibrosis. This information can lead to a clinically relevant diagnostic/prognostic biomarker for NASH...
  67. doi request reprint Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets
    Z M Younossi
    Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA
    Aliment Pharmacol Ther 39:3-14. 2014
    ..Many therapeutic options for NASH have been studied. However, there is very little evidence supporting the efficacy of most regimens for the treatment of NASH...
  68. doi request reprint Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C
    Z M Younossi
    Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA
    J Viral Hepat 20:550-5. 2013
    ..Therefore, birth cohort screening of the U.S. General population could lead to wider identification of HCV and potentially better management of the future burden of HCV and its complications...
  69. ncbi request reprint Study of host and virological factors of patients with chronic HCV infection and associated laboratory or clinical autoimmune manifestations
    D Vassilopoulos
    Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Clin Exp Rheumatol 21:S101-11. 2003
    ..The goals of our study were to identify host and/or virological factors that are implicated in the pathogenesis of these manifestations...
  70. ncbi request reprint Hepatitis C, cryoglobulinemia, and cutaneous vasculitis associated with unusual and serious manifestations
    P Mendez
    Department of Medicine, University of Miami School of Medicine, Florida 33136, USA
    Am J Gastroenterol 96:2489-93. 2001
    ..v. immunoglobulin, and plasmapheresis. Our report underscores the importance of recognizing nonhepatic manifestations in patients with hepatitis C infection that may be associated with high morbidity and mortality...
  71. doi request reprint Hepatitis C virus infection, age, and Hispanic ethnicity increase mortality from liver cancer in the United States
    Zobair M Younossi
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, Virginia 22042, USA
    Clin Gastroenterol Hepatol 8:718-23. 2010
    ..We performed a population-based study to assess factors that are associated independently with hepatocellular carcinoma (HCC)-related mortality...
  72. ncbi request reprint Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance
    Ancha Baranova
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Obes Surg 16:1118-25. 2006
    ....
  73. ncbi request reprint Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome
    Chin Hee Kim
    Center for Liver Diseases INOVA Fairfax Hospital, Falls Church, VA 22042, USA
    Cleve Clin J Med 75:721-8. 2008
    ..There is no established treatment for NAFLD except for weight loss and treating each component of the metabolic syndrome...
  74. doi request reprint Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index
    Amy A Dan
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22003 6800, USA
    Liver Transpl 14:321-6. 2008
    ..In conclusion, SF-6D provides not only a generic assessment of HRQL but also a utility score that can be used for economic analysis of patients with chronic liver disease...
  75. ncbi request reprint Microarray technology in the study of obesity and non-alcoholic fatty liver disease
    Ancha Baranova
    Center for the Study of Genomics in Liver Diseases, Molecular and Microbiology Department, George Mason University and Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Liver Int 25:1091-6. 2005
    ..Over the next few years, advances in technology and refinements in study design and data analysis will make clinically relevant translational research even more engaging and productive...
  76. doi request reprint Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response
    Zobair M Younossi
    Inova Fairfax Hospital, Falls Church, VA, USA
    Liver Int 29:3-12. 2009
    ..Clinically, these data suggest that attention must be paid not only to optimizing antiviral response but also to screening for and treatment of the various components of the metabolic syndrome...
  77. doi request reprint A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH)
    Zobair M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA, 22042, USA
    Obes Surg 18:1430-7. 2008
    ..Recent findings suggest a role for apoptosis and adipocytokines in the pathogenesis of NASH. The aim of this study was to develop a noninvasive diagnostic biomarker for NASH...
  78. doi request reprint Metabolic syndrome after laparoscopic bariatric surgery
    Clare Nugent
    Center for Liver Diseases, Inova Fairfax Hospital and Translational Research Institute, 3300 Gallows Road, Falls Church, VA, 22042, USA
    Obes Surg 18:1278-86. 2008
    ..Metabolic syndrome (MS) is common among morbidly obese patients undergoing bariatric surgery. The aim of this study was to assess the impact and predictors of bariatric surgery on the resolution of MS...
  79. ncbi request reprint Pathologic assessment of non-alcoholic fatty liver disease
    Silvia Bondini
    Center for Liver Diseases at Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Clin Liver Dis 11:17-23, vii. 2007
    ..This article reviews some of the studies dealing with the histopathology of NAFLD, with attempts to develop a standardized pathologic scoring system for NASH...
  80. ncbi request reprint Obesity-related differential gene expression in the visceral adipose tissue
    Ancha Baranova
    Center for the Study of Genomics in Liver Diseases, Molecular and Microbiology Department, George Mason University, VA, USA
    Obes Surg 15:758-65. 2005
    ..This study investigates the expression patterns in human adipose tissue, and identifies genes that may be involved in the abnormal energy homeostasis...
  81. ncbi request reprint A 2012 clinical update for internists in adult nonalcoholic fatty liver disease
    Z M Younossi
    Department of Internal Medicine, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Panminerva Med 54:29-37. 2012
    ..In this article, we aim to provide an update to clinicians related to issues surrounding prognosis, monitoring, and treatment...
  82. ncbi request reprint Non-alcoholic fatty liver disease and hepatitis C infection
    S Bondini
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Virginia 22042, USA
    Minerva Gastroenterol Dietol 52:135-43. 2006
    ..Thus, the management of obesity and metabolic syndrome in patients with chronic hepatitis C may be important for reducing the risk of progression as well as improving the efficacy of antiviral therapy...
  83. doi request reprint Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study
    Maria Stepanova
    Center for Liver Diseases at Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Gut 59:1410-5. 2010
    ..Chronic liver disease (CLD) is a major cause of mortality and morbidity worldwide. The aim of this study was to assess the overall and liver-related mortality and their predictors in patients with CLD using population data...
  84. ncbi request reprint Monoclonal and polyclonal antibodies against the HCV envelope proteins
    Heshaam M Mir
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Clin Liver Dis 13:477-86. 2009
    ..Monoclonal and polyclonal antibodies present an important therapeutic option in this area, and this article assesses current investigations of several antibodies...
  85. ncbi request reprint Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C
    Nila Rafiq
    Center for Liver Diseases at Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Expert Rev Gastroenterol Hepatol 2:207-15. 2008
    ..g., HCV genotype 3). Increasing evidence suggests that hepatic steatosis, insulin resistance and obesity in the setting of HCV have a negative impact on the efficacy of treatment and hepatic progression of fibrosis...
  86. ncbi request reprint Impact of non-alcoholic fatty liver disease on chronic hepatitis B
    Silvia Bondini
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA 22003 6800, USA
    Liver Int 27:607-11. 2007
    ..Aim: This study aims to evaluate the prevalence of NAFLD in patients with CH-B and the association with viral and host factors, particularly in patients with metabolic syndrome (MS)...
  87. ncbi request reprint Epidemiology and natural history of NAFLD and NASH
    Janus P Ong
    Center for Liver Diseases, Inova Fairfax Hospital, 3289 Woodburn Road, Annadale, VA 22003, USA
    Clin Liver Dis 11:1-16, vii. 2007
    ..NASH-related cirrhosis may have a similar prognosis as cirrhosis from other causes, leading to liver failure or hepatocellular carcinoma...
  88. ncbi request reprint MELD fails to measure quality of life in liver transplant candidates
    Sammy Saab
    Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, CA 90095, USA
    Liver Transpl 11:218-23. 2005
    ..The presence of ascites and/or encephalopathy was significantly associated with poor quality of life. CTP correlates better to QOL, probably because it contains ascites and encephalopathy...
  89. ncbi request reprint A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis
    Valerie S Calvert
    George Mason Inova Health System s Translational Research Centers, VA, USA
    Hepatology 46:166-72. 2007
    ..Specific insulin pathway signaling events are altered in the adipose tissue of patients with NASH compared with patients with nonprogressive forms of NAFLD...
  90. ncbi request reprint Evaluation and management of obesity-related nonalcoholic fatty liver disease
    Clare Nugent
    Inova Fairfax Hospital Annandale, VA 22042, USA
    Nat Clin Pract Gastroenterol Hepatol 4:432-41. 2007
    ..As yet there is no convincingly effective treatment for NAFLD--a multimodal treatment plan that targets obesity, insulin resistance, hyperlipidemia and hypertension might be the best option for these patients...
  91. ncbi request reprint Health-related quality of life in patients with chronic hepatitis B
    Silvia Bondini
    Center for Liver Diseases, Inova Fairfax Hospital, Fairfax, VA, USA
    Liver Int 27:1119-25. 2007
    ..Although chronic hepatitis C (CH-C) has consistently been shown to impair patients' health-related quality of life (HRQL), the impact of chronic hepatitis B (CH-B) on HRQL has not been fully explored...
  92. ncbi request reprint Pathologic features associated with fibrosis in nonalcoholic fatty liver disease
    Terry Gramlich
    Cleveland Clinic Foundation, OH, USA
    Hum Pathol 35:196-9. 2004
    ..We conclude that the presence of hepatocyte injury in NAFLD is associated with fibrosis. These pathological features can be used to establish the pathological criteria for diagnosis of the progressive form of NAFLD or NASH...
  93. ncbi request reprint Non-alcoholic fatty liver disease: an overview
    Brian P Mulhall
    Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, Virginia 22042, USA
    J Gastroenterol Hepatol 17:1136-43. 2002
    ..It is anticipated that, through a better understanding of NAFL, more effective treatment protocols can be developed targeting only those patients with NASH that are at the highest risk for progression to cirrhosis and liver failure...
  94. doi request reprint Long-term follow-up of patients with nonalcoholic fatty liver
    Nila Rafiq
    Center for Liver Diseases, Inova Health System, Annandale, Virginia, USA
    Clin Gastroenterol Hepatol 7:234-8. 2009
    ..NASH is the only subtype of NAFLD that has been shown to progress relatively, although these findings were reported from studies with short follow-up periods. We assessed the long-term outcomes of a NAFLD cohort...
  95. ncbi request reprint Nonalcoholic fatty liver disease and the epidemic of obesity
    Rochelle Collantes
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA 22042 3300, USA
    Cleve Clin J Med 71:657-64. 2004
    ..Nonalcoholic fatty liver disease (NAFLD) is common in patients with the metabolic syndrome, and it is expected to become more common in countries where obesity, one of the components of the metabolic syndrome, is increasing...
  96. ncbi request reprint Risk factors for hepatocellular carcinoma in patients with cirrhosis
    Steedman A Sarbah
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, Virginia 22042, USA
    Dig Dis Sci 49:850-3. 2004
    ..8 [1.9-134]; P = 0.01). Iron studies did not reveal an increased risk for iron overload or HFE mutation. Male gender, advancing age, and non-Caucasian ethnic background are independently associated with HCC...
  97. ncbi request reprint The utility of radiological imaging in nonalcoholic fatty liver disease
    Sherif Saadeh
    Department of Gastroenterology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Gastroenterology 123:745-50. 2002
    ..This prospective study evaluates the role of radiological modalities in establishing the diagnosis of nonalcoholic steatohepatitis (NASH)...
  98. ncbi request reprint The impact of liver disease on health-related quality of life: a review of the literature
    Lisa M Martin
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Curr Gastroenterol Rep 4:79-83. 2002
    ..In this article, we review the recent research that has examined the impact of chronic liver disease on health-related quality of life...
  99. ncbi request reprint Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease
    Ancha Baranova
    Center for Liver Diseases, Inova Fairfax Hospital, VA, USA
    Expert Rev Mol Diagn 7:195-205. 2007
    ..Potential therapeutic applications are also considered...
  100. ncbi request reprint Approach to the diagnosis and treatment of nonalcoholic fatty liver disease
    Janus P Ong
    Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Clin Liver Dis 9:617-34, vi. 2005
    ..This article describes the epidemiology, clinical features, natural history, and pathogenesis of NAFLD...
  101. ncbi request reprint Treatment regimens for non-alcoholic fatty liver disease
    Brian P Lam
    Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA 22042, USA
    Ann Hepatol 8:S51-9. 2009
    ....